TN2016000142A1 - Specific anti-cd38 antibodies for treating human cancers. - Google Patents
Specific anti-cd38 antibodies for treating human cancers.Info
- Publication number
- TN2016000142A1 TN2016000142A1 TN2016000142A TN2016000142A TN2016000142A1 TN 2016000142 A1 TN2016000142 A1 TN 2016000142A1 TN 2016000142 A TN2016000142 A TN 2016000142A TN 2016000142 A TN2016000142 A TN 2016000142A TN 2016000142 A1 TN2016000142 A1 TN 2016000142A1
- Authority
- TN
- Tunisia
- Prior art keywords
- antibody
- antibodies
- medicament
- specific anti
- human cancers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898309P | 2013-10-31 | 2013-10-31 | |
| EP14306220 | 2014-07-31 | ||
| PCT/US2014/063380 WO2015066450A1 (en) | 2013-10-31 | 2014-10-31 | Specific anti-cd38 antibodies for treating human cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2016000142A1 true TN2016000142A1 (en) | 2017-10-06 |
Family
ID=51266255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2016000142A TN2016000142A1 (en) | 2013-10-31 | 2014-10-31 | Specific anti-cd38 antibodies for treating human cancers. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20150118251A1 (enExample) |
| EP (2) | EP3805266A1 (enExample) |
| JP (3) | JP2016536314A (enExample) |
| KR (1) | KR20160077155A (enExample) |
| CN (1) | CN106103481A (enExample) |
| AU (1) | AU2014342103B2 (enExample) |
| BR (1) | BR112016009403A2 (enExample) |
| CA (1) | CA2927099A1 (enExample) |
| CR (1) | CR20160186A (enExample) |
| EA (1) | EA035098B1 (enExample) |
| IL (1) | IL245196B (enExample) |
| MA (2) | MA39070A1 (enExample) |
| MX (1) | MX373301B (enExample) |
| NZ (1) | NZ719784A (enExample) |
| PL (1) | PL3063173T3 (enExample) |
| PT (1) | PT3063173T (enExample) |
| SG (2) | SG10201803288RA (enExample) |
| TN (1) | TN2016000142A1 (enExample) |
| TW (1) | TW201522378A (enExample) |
| WO (1) | WO2015066450A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| PL2968555T3 (pl) | 2013-03-13 | 2020-11-16 | Sanofi | Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3191187B1 (en) | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| JP6802791B2 (ja) | 2014-12-04 | 2020-12-23 | ヤンセン バイオテツク，インコーポレーテツド | 急性骨髄性白血病の治療のための抗ｃｄ３８抗体 |
| PL3294769T3 (pl) * | 2015-05-13 | 2021-07-05 | Morphosys Ag | Leczenie szpiczaka mnogiego (mm) |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| JP6771492B2 (ja) | 2015-05-30 | 2020-10-21 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | 脱免疫化された志賀毒素ａサブユニット足場及びそれを含む細胞標的化分子 |
| WO2016201337A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers |
| NZ777133A (en) | 2015-06-22 | 2025-05-02 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| MD3827845T2 (ro) * | 2015-11-03 | 2022-09-30 | Janssen Biotech Inc | Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora |
| AU2017226960B2 (en) | 2016-03-04 | 2024-03-21 | Morphosys Ag | Clinical assessment of M-protein response in multiple myeloma |
| WO2017223111A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3484923A1 (en) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
| HRP20240767T1 (hr) | 2016-09-14 | 2024-09-13 | Teneoone, Inc. | Cd3 vezujuća antitijela |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio, Inc. | anticorpos apenas de cadeia pesada anti-bcma |
| MX2019015563A (es) | 2017-06-20 | 2020-07-28 | Teneoone Inc | Anticuerpos anti-bcma unicamente de cadena pesada. |
| CN110891971B (zh) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| JPWO2019031444A1 (ja) * | 2017-08-07 | 2020-08-27 | 国立大学法人九州大学 | 細胞集団における特異的結合物質の占有率を測定する方法 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3075399A1 (en) * | 2017-09-13 | 2019-03-21 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| EP3704156A1 (en) | 2017-11-03 | 2020-09-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| CN112739715A (zh) | 2018-01-12 | 2021-04-30 | 武田药品工业株式会社 | 抗cd38抗体的皮下给药 |
| US20210047427A1 (en) * | 2018-03-28 | 2021-02-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| CN112703038B (zh) * | 2018-07-10 | 2025-07-29 | 赛诺菲 | 靶向CD38和TGF-β的抗癌组合疗法 |
| KR20210104736A (ko) | 2018-12-14 | 2021-08-25 | 모르포시스 아게 | 항체 제형 |
| WO2020188573A1 (en) * | 2019-03-21 | 2020-09-24 | Gamida-Cell Ltd. | Expanded nk cell fractions for transplantation in combination therapy |
| AU2020252556B2 (en) | 2019-04-05 | 2026-02-05 | Teneobio, Inc. | Heavy chain antibodies binding to PSMA |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| TW202133879A (zh) | 2019-12-05 | 2021-09-16 | 美商賽諾菲阿凡提斯美國有限責任公司 | 用於皮下投予之抗cd38抗體的調配物 |
| CA3164026A1 (en) * | 2019-12-06 | 2021-06-10 | Sanofi-Aventis U.S. Llc | Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma |
| WO2021259227A1 (zh) * | 2020-06-23 | 2021-12-30 | 江苏康缘药业股份有限公司 | 抗cd38抗体及其用途 |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| EP4612177A1 (en) * | 2022-10-31 | 2025-09-10 | Genmab A/S | Cd38 antibodies and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN1976950B (zh) * | 2004-02-06 | 2012-08-29 | 莫佛塞斯公司 | 抗cd38人抗体及其用途 |
| EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| US20090123950A1 (en) * | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
| NZ576122A (en) * | 2006-09-26 | 2012-09-28 | Genmab As | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| EP3559049B1 (en) * | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| PL2968555T3 (pl) * | 2013-03-13 | 2020-11-16 | Sanofi | Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib |
-
2014
- 2014-10-31 US US14/529,719 patent/US20150118251A1/en not_active Abandoned
- 2014-10-31 CN CN201480071448.0A patent/CN106103481A/zh active Pending
- 2014-10-31 EP EP20188077.0A patent/EP3805266A1/en not_active Withdrawn
- 2014-10-31 KR KR1020167013974A patent/KR20160077155A/ko not_active Ceased
- 2014-10-31 MA MA39070A patent/MA39070A1/fr unknown
- 2014-10-31 SG SG10201803288RA patent/SG10201803288RA/en unknown
- 2014-10-31 BR BR112016009403A patent/BR112016009403A2/pt not_active Application Discontinuation
- 2014-10-31 TW TW103137932A patent/TW201522378A/zh unknown
- 2014-10-31 SG SG11201603088RA patent/SG11201603088RA/en unknown
- 2014-10-31 PL PL14799089T patent/PL3063173T3/pl unknown
- 2014-10-31 CA CA2927099A patent/CA2927099A1/en not_active Abandoned
- 2014-10-31 MA MA44560A patent/MA44560B2/fr unknown
- 2014-10-31 AU AU2014342103A patent/AU2014342103B2/en active Active
- 2014-10-31 PT PT147990899T patent/PT3063173T/pt unknown
- 2014-10-31 MX MX2016005666A patent/MX373301B/es active IP Right Grant
- 2014-10-31 NZ NZ719784A patent/NZ719784A/en unknown
- 2014-10-31 JP JP2016527374A patent/JP2016536314A/ja active Pending
- 2014-10-31 EA EA201690905A patent/EA035098B1/ru not_active IP Right Cessation
- 2014-10-31 WO PCT/US2014/063380 patent/WO2015066450A1/en not_active Ceased
- 2014-10-31 EP EP14799089.9A patent/EP3063173B1/en active Active
- 2014-10-31 TN TN2016000142A patent/TN2016000142A1/en unknown
-
2016
- 2016-04-19 IL IL245196A patent/IL245196B/en active IP Right Grant
- 2016-04-21 CR CR20160186A patent/CR20160186A/es unknown
-
2017
- 2017-04-05 US US15/479,500 patent/US20180022814A1/en not_active Abandoned
-
2023
- 2023-05-24 JP JP2023085105A patent/JP2023109927A/ja active Pending
-
2025
- 2025-05-07 JP JP2025077126A patent/JP2025139586A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA44560A1 (fr) | 2019-09-30 |
| MX373301B (es) | 2020-04-24 |
| MX2016005666A (es) | 2016-07-14 |
| CR20160186A (es) | 2016-06-13 |
| CA2927099A1 (en) | 2015-05-07 |
| JP2023109927A (ja) | 2023-08-08 |
| EP3805266A1 (en) | 2021-04-14 |
| IL245196B (en) | 2021-04-29 |
| PL3063173T3 (pl) | 2021-01-11 |
| JP2025139586A (ja) | 2025-09-26 |
| SG11201603088RA (en) | 2016-05-30 |
| MA44560B2 (fr) | 2021-01-29 |
| JP2016536314A (ja) | 2016-11-24 |
| WO2015066450A1 (en) | 2015-05-07 |
| TW201522378A (zh) | 2015-06-16 |
| AU2014342103B2 (en) | 2020-06-04 |
| AU2014342103A1 (en) | 2016-05-26 |
| CN106103481A (zh) | 2016-11-09 |
| NZ719784A (en) | 2022-02-25 |
| MA44560B1 (fr) | 2020-06-30 |
| EA035098B1 (ru) | 2020-04-27 |
| MA39070A1 (fr) | 2017-11-30 |
| SG10201803288RA (en) | 2018-05-30 |
| BR112016009403A2 (pt) | 2017-09-19 |
| IL245196A0 (en) | 2016-06-30 |
| US20150118251A1 (en) | 2015-04-30 |
| KR20160077155A (ko) | 2016-07-01 |
| EA201690905A1 (ru) | 2016-08-31 |
| PT3063173T (pt) | 2020-10-20 |
| EP3063173B1 (en) | 2020-07-29 |
| US20180022814A1 (en) | 2018-01-25 |
| EP3063173A1 (en) | 2016-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2016000142A1 (en) | Specific anti-cd38 antibodies for treating human cancers. | |
| EA201691747A1 (ru) | Варианты комбинированной терапии с антителами анти-cd38 | |
| PH12016501672A1 (en) | Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| PH12016500677A1 (en) | Specific anti-cd38 antibodies for treating human cancers | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| PH12017500493A1 (en) | Combination therapy | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| EA033400B1 (ru) | Антитело против cd3 и его применение | |
| SG10201908388UA (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| MY193524A (en) | Diaryl macrocycles as modulators of protein kinases | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| MX368228B (es) | Anticuerpos que se unen específicamente a her2. | |
| MX380557B (es) | Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm). | |
| ZA202102438B (en) | Melflufen dosage regimens for cancer | |
| CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2016006894A (es) | Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. | |
| IN2013MU03118A (enExample) | ||
| TW201613599A (en) | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease | |
| WO2015051234A3 (en) | Tweak antagonists for treating lupus nephritis and muscle atrophy | |
| MX2019003368A (es) | Agentes anticancerigenos y preparacion de los mismos. | |
| MX2017013669A (es) | Composiciones para el tramiento del cancer. | |
| WO2016094341A8 (en) | Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer |